Tirzepatide API with a molecular weight of 4,813.5 Da is processed into a preservative-free aqueous solution at six graduated strengths, each delivered in a 0.5 mL subcutaneous dose. The quantitative composition per 0.5 mL is fixed for the excipients across all six strengths: 4.0 mg sodium chloride, 0.63 mg sodium phosphate dibasic heptahydrate, 0.22 mg sodium phosphate monobasic monohydrate, and Water for Injection to volume. The active pharmaceutical ingredient concentration ranges from 5 mg/mL for the 2.5 mg dose to 30 mg/mL for the 15 mg dose, and pH is adjusted to 6.5–7.5 with sodium hydroxide or hydrochloric acid. Aseptic processing is mandatory because the peptide cannot withstand terminal moist-heat sterilization; the solution is compounded in closed vessels, passed through 0.22 µm sterilizing-grade membranes, and filled into single-dose prefilled pen cartridges under Grade A conditions. The terminal finished product is a single-dose disposable prefilled pen intended for subcutaneous administration and stored at 2–8°C protected from light; if a patient-level temperature excursion is unavoidable, the pen may be held at not more than 30°C for up to 21 days before discard. Release testing for this presentation includes USP <71> sterility, USP <85> bacterial endotoxins, USP <787> subvisible particulate matter, and USP <790> visible particulates.

On commercial fill-finish lines, the 0.5 mL fill volume is controlled by low-shear rotary piston pumps or peristaltic systems that minimize peptide aggregation at the air-liquid interface; 100% gravimetric check-weighing is used to reject individual pens when fill weight deviates from the validated target. Silicone oil, used to lubricate the glass cartridge and plunger, is a known aggregation interface for amphiphilic peptides, so siliconization levels are controlled and monitored by extraction or total carbon methods during component qualification. Device assembly is governed by ISO 11608-1:2022 for needle-based injection systems, and the pen must meet dose accuracy, retained volume, and cap removal torque requirements before batch release. Visual inspection of the filled cartridges is performed after assembly, and any cartridge exhibiting visible fibers, glass lamellae, or foreign matter is rejected under USP <790> criteria. The fill-finish process is validated for filter compatibility, filter adsorption, hold time, and pre- and post-use integrity testing of the sterilizing-grade filters; production hold times for the compounded solution are established by bioburden and endotoxin recovery data rather than assumed.

Single-Dose Vial Processing and the Residual Seal Force Window

Single-dose vial processing shares the approved solution composition with the prefilled pen but differs in the container closure system and the failure modes that govern release. The six strengths in Table 1 are filled into Type I borosilicate glass vials at a nominal volume of 0.5 mL; because the vial is not designed to be self-administered, the healthcare professional withdraws the dose using a separate syringe and needle, which shifts the critical quality attribute from pen dose accuracy to vial deliverable volume. Stopper compression after steam sterilization and crimping is monitored as residual seal force because low-fill vials have a smaller headspace and are less tolerant of seal relaxation during cold-chain distribution. Elastomeric closures are qualified under USP <381>, and the vial-stopper-crimp system is validated by deterministic container closure integrity testing according to USP <1207>, with vacuum decay or helium leak methods selected to match the low-volume headspace. The filling line operates under EU GMP Annex 1:2022 Grade A air supply in a Grade B background; vials are depyrogenated in a dry-heat tunnel, and the sterile solution is filled using gravimetric control with 100% check-weighing before stoppering and crimping. Because the vial contains a single dose and no antimicrobial preservative, any unused portion is discarded after withdrawal; this terminal finished product is stocked at 2–8°C and protected from light, with the same 21-day room-temperature excursion allowance as the pen presentation only when permitted by local labeling.

Deliverable volume testing under USP <698> is product-specific because the small fill volume and the viscosity of the solution require alignment of syringe and needle geometry with the labeled withdrawal volume. Visual inspection of the vial after crimping includes side-wall and bottom illumination against black and white backgrounds; automated inspection systems must differentiate glass defects from product-related particles. The residual seal force acceptance window is established during qualification using production-scale stoppering heads and is not transferable across stopper formulations or vial neck geometries; published data for a universal residual seal force limit in tirzepatide vials is limited. Cold-chain distribution studies include freeze-thaw excursion monitoring because accidental freezing causes phase separation and peptide aggregation in liquid formulations; product exposed to frozen conditions is discarded under stability instructions.

When tirzepatide is listed on a regulatory shortage register, 503B outsourcing facilities may prepare sterile subcutaneous injection using the same quantitative composition as the approved liquid product, but the regulatory framework and release testing differ from those of the marketing authorization holder. A compounded 15 mg/0.5 mL formulation requires 30 mg/mL tirzepatide, 8.0 mg/mL sodium chloride, 1.26 mg/mL sodium phosphate dibasic heptahydrate, and 0.44 mg/mL sodium phosphate monobasic monohydrate, adjusted to pH 6.5–7.5. Compliance is governed by FD&C Act Section 503B, FDA 21 CFR 210/211, and USP <797> for compounded sterile preparations; sterility and endotoxin testing follow USP <71> and USP <85>. The production process uses an ISO 5 hood or isolator for aseptic handling, dissolution of the API in Water for Injection, sterile filtration through a 0.22 µm membrane, and filling into single-dose vials or syringes; because no preservative is present, multi-dose packaging is not used. The terminal finished product is a single-dose sterile solution for subcutaneous administration distributed to hospitals, clinics, and physician offices rather than retail pharmacies. Published data on long-term stability of these outsourced preparations is limited compared with the approved product; beyond-use dating is assigned under USP <797> rather than from a full ICH stability program.

Batch-to-batch variance in this track often arises from differences in API physical form, mixing shear, and sterile filter adsorption, not from the qualitative formula. Facilities must qualify each source of tirzepatide API for identity, assay, endotoxin, and particulate behavior before use, because particle formation in compounded solutions has been observed when pH is adjusted too rapidly or when the peptide is exposed to stainless-steel surfaces for extended hold times. 503B operations are required to maintain a current site registration and to report products under FDA 21 CFR 207; the final container label must identify the facility as a 503B outsourcing facility and include the assigned beyond-use date. The absence of a pharmacopeial monograph for tirzepatide means that each outsourcing facility establishes in-house specifications for potency and purity, typically by validated high-performance liquid chromatography with peptide mapping or by another stability-indicating method.

What Limits Primary Drying Time When Mannitol Crystallizes in Lyophilized Tirzepatide?

Lyophilized tirzepatide is not a market-authorized commercial presentation; downstream development work on freeze-dried powder is directed at reducing cold-chain dependence or extending shelf life in non-ideal storage conditions. The primary drying rate is limited by the collapse temperature of the frozen matrix and by the thermal history of the bulking agent. Candidate formulations screen mannitol or trehalose at mass ratios from 2:1 to 5:1 relative to peptide, with mannitol supplying crystalline mechanical rigidity and trehalose forming an amorphous protective glass around the peptide. If mannitol is crystallized during an annealing step held near -15°C to -20°C, the lyophilized cake becomes mechanically stable but the peptide may partition into residual amorphous regions where molecular mobility is higher; freeze-drying microscopy and differential scanning calorimetry are therefore used to determine the glass transition temperature of the maximally freeze-concentrated solute and the mannitol eutectic melting temperature before cycle design. Published data for a specific tirzepatide lyophilization formula are limited; generic cycle parameters cannot be substituted for product-specific thermal characterization. Process validation is conducted under ICH Q1A(R2) stability guidance and ICH Q8(R2) pharmaceutical development; residual moisture is measured by USP <921> and water activity by USP <922>.

The production process consists of sterile filtration of the formulated solution into molded or tubing vials, partial insertion of lyophilization stoppers, freezing to -40°C or lower, annealing at subzero temperatures where mannitol crystallization is desired, primary drying under vacuum with shelf temperature held 2–5°C below the measured collapse temperature, and secondary drying at 20–40°C to achieve a residual moisture target of not more than 1.0% by weight. Terminal product is a lyophilized powder for reconstitution with Water for Injection immediately before subcutaneous use; the reconstituted solution must meet the same sterility, endotoxin, and subvisible particulate acceptance criteria as the liquid injection. Because the freeze-dried route introduces reconstitution time, residual moisture sensitivity, and possible cake collapse defects, it remains a development-stage option rather than a routine commercial presentation.

Oral tablet, capsule, and granule presentations of tirzepatide API are not part of the authorized commercial supply chain, and the peptide exhibits negligible oral bioavailability in the absence of a permeability enhancer. Feasibility batches for preclinical and early clinical pharmacokinetic work are produced by CDMOs as research-grade oral formulations, but these are not substitutable for the injectable product. The only approved oral peptide in the same therapeutic class uses 300 mg salcaprozate sodium as a permeation enhancer with 14 mg semaglutide; direct extrapolation of that ratio to tirzepatide is not scientifically valid because the two peptides differ in molecular weight, net charge, and proteolytic susceptibility. No compendial formulation addition ratio exists for oral tirzepatide, and published data for a specific oral tirzepatide tablet or capsule formula is limited. Compliance for such feasibility work falls under FDA 21 CFR Part 58 for nonclinical laboratory studies, ICH M3(R2) for nonclinical safety evaluation, and 21 CFR Part 11 for electronic records generated during analytical testing. The downstream process for feasibility capsules generally involves spray-drying a peptide-enhancer dispersion onto a protective matrix and filling the resulting powder into hard gelatin or hypromellose capsules at laboratory scale; direct compression into tablets is used less often because the shear and thermal input during roller compaction can induce aggregation. Wet granulation is avoided unless the enhancer system is specifically designed to stabilize the peptide during aqueous binder addition. Terminal finished product is a research-use capsule or tablet intended only for animal studies or early-phase human pharmacokinetic protocols; it is not distributed as a commercial finished dosage form.